Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Neoplasms 2Hematologic Diseases 2Thrombocytosis 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Polycythemia 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hemorrhagic Disorders 1EGFR Mutated EGFR TKI Naive Metastatic NSCLC 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

ruxolitinib 4Specimen Handling 3Biopsy 3venetoclax 2trametinib 1sonidegib 1siltuximab 1regorafenib 1ponatinib 1pomalidomide 1pevonedistat 1pertuzumab 1pembrolizumab 1pelcitoclax 1peginterferon alfa-2b 1palbociclib 1olaparib 1neratinib 1luspatercept 1lorlatinib 1lenvatinib 1itacitinib 1imetelstat 1idelalisib 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocytosis × N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all
NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡